Merrill Lynch maintains NeoPharm at buy

NeoPharm, Inc. was maintained by Merrill Lynch analyst David Munno at a buy rating after the company announced that Guillermo Herrera, former exec at Abbott International, will replace Ron Eidell as chief executive officer and president. Merrill Lynch said it believes the change brings needed commercial and drug launch experience, along with stability to a position that has seen rampant turnover. Shares of the Lake Forest, Ill.-based biopharmaceutical company were up $0.55, or 6.07%, at $9.61 on volume of 245,968 shares versus the three-month running average of 303,008 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.